Biohaven Ltd
BHVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.21B
Close$
$-0.51
103.5% downside
Current Fair Value
103.5% downsideOvervalued by 103.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.21 Billion |
|---|---|
| Enterprise Value | $2.21 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.86 |
| Beta | 3.14 |
| Outstanding Shares | 147,615,197 |
Return
| Return on Equity | -500.14% |
|---|---|
| Return on Assets | -138.87% |
| Return on Invested Capital | -159.43% |
Valuation & Multiples
| P/E Ratio | -2.59 |
|---|---|
| PEG | 6.29 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.35 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 2.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
$490,492
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 25.50% |
|---|---|
| Total Calls | 806▼ 99.96% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.41%▼ 99.72% |
|---|---|
| Total Invested | $404.41M▼ 66.34% |
| Investors Holding | 107▼ 186.00% |
ESG Score
No data
About Biohaven Pharmaceutical Holding Company Ltd
CEO: Vlad Coric